MedTrace Logo

Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis

NCT02637310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2016-03-30

No results posted yet for this study

Summary

A multi center, randomized, double-blind, placebo-controlled, parallel, phase 2b clinical trial to evaluate the efficacy and safety of N02RS1 in patients with acute bronchitis

Conditions

  • Acute Bronchitis

Interventions

DRUG

N02RS1 1200mg

1200mg/day, Three times a day orally, 2 tablets once, 7 days

DRUG

Placebo

1200mg/day, Three times a day orally, 2 tablets once, 7 days

Sponsors & Collaborators

  • PharmaKing

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-03-31
Completion
2016-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02637310 on ClinicalTrials.gov